NCT00077181View on ClinicalTrials.gov

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

July 31, 2008

Conditions
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous LeukemiaSecondary Acute Myeloid Leukemia
Interventions
DRUG

cytarabine

Given IV

DRUG

triapine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00077181 - 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter